{"product_id":"huons-business-model-canvas","title":"Huons Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuons Business Model Canvas: Core Blueprint for Value, Partners \u0026amp; Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic blueprint behind Huons with our concise Business Model Canvas—showcasing value propositions, customer segments, key partners, and revenue levers that drive its growth and resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Strategic Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHuons partners with global distributors to place its proprietary toxins and fillers across North America, Europe, and Southeast Asia; these channels handled roughly 42% of Huons’ 2024 export revenue of KRW 132 billion (USD 99M) and expand patient reach to 18+ countries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Academic Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHuons partners with universities and specialized research centers to co-develop drug delivery systems and new chemical entities, supporting over 20 joint R\u0026amp;D projects since 2022 and sharing research costs of roughly KRW 12 billion (~USD 9.0M) through 2024.\u003c\/p\u003e\n\u003cp\u003eThese collaborations feed Huons’ ophthalmology and dermatology pipeline, underpinning 6 patent filings in 2023–2025 and helping sustain a 12% R\u0026amp;D-driven revenue growth trajectory versus peers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material and API Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSecuring reliable active pharmaceutical ingredient (API) and specialized raw material suppliers is vital for Huons to keep production stable and meet strict quality specs; in 2024 Huons reported 92% on-time supply for key APIs, reducing stockouts by 38% year-on-year. Huons maintains long-term contracts with global chemical providers, using dual-sourcing and volume-based pricing to cut procurement costs ~6% and protect output for high-purity medical devices and injectables where consistency is non-negotiable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHuons treats contract manufacturing clients as strategic partners, providing CMO\/CDMO services with joint technical integration and unified quality standards to manufacture pills, injectables, and biosimilars; in 2024 Huons’ CMO revenue was approx. KRW 120 billion, driving ~28% facility utilization uplift versus standalone production.\u003c\/p\u003e\n\u003cp\u003eThese partnerships optimize asset use and give Huons early visibility into industry tech shifts—helping prioritize investments in single-use tech and continuous manufacturing to meet rising third-party demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 CMO revenue ~KRW 120 billion\u003c\/li\u003e\n\u003cli\u003e~28% uplift in facility utilization\u003c\/li\u003e\n\u003cli\u003eDosage forms: oral, injectable, biosimilars\u003c\/li\u003e\n\u003cli\u003eInvestment focus: single-use, continuous manufacturing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Societies and Clinical Experts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngaging medical societies and Key Opinion Leaders (KOLs) lets Huons validate products via clinical trials and peer-reviewed studies—e.g., 2024 collaborations produced 3 multicenter trials and 2 published papers, improving regulatory approval odds and speeding time-to-market by ~6 months.\u003c\/p\u003e\n\u003cp\u003eKOL feedback shapes device safety and efficacy updates, keeping products aligned with practitioner needs and standards; ongoing ties cut post-market issues 18% in recent programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 multicenter trials (2024)\u003c\/li\u003e\n\u003cli\u003e2 peer-reviewed papers (2024)\u003c\/li\u003e\n\u003cli\u003e~6 months faster time-to-market\u003c\/li\u003e\n\u003cli\u003e18% fewer post-market issues\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuons scales toxins \u0026amp; fillers globally: 42% exports, KRW132bn, faster launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHuons leverages global distributors, research centers, API suppliers, CMOs, and KOLs to scale toxins\/fillers and pipelines—42% of 2024 export revenue (KRW 132bn), 20+ joint R\u0026amp;D projects (KRW 12bn cost-share), 92% API on-time supply, KRW 120bn CMO revenue, 3 multicenter trials (2024), 6% faster launches, 18% fewer post-market issues.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport share via partners\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport revenue\u003c\/td\u003e\n\u003ctd\u003eKRW 132bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJoint R\u0026amp;D projects\u003c\/td\u003e\n\u003ctd\u003e20+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D cost-share\u003c\/td\u003e\n\u003ctd\u003eKRW 12bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI on-time\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO revenue\u003c\/td\u003e\n\u003ctd\u003eKRW 120bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMulticenter trials\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Huon detailing customer segments, channels, value propositions, key activities, resources, partners, cost structure and revenue streams, aligned to real-world operations and investor needs to support presentations, funding discussions and strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Huon’s strategy into a digestible one-page snapshot with editable cells, saving hours of formatting while enabling quick comparison, team collaboration, and fast executive deliverables.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHuons invests heavily in discovery and development of novel therapeutics and biosimilars, focusing on ophthalmology and chronic diseases; R\u0026amp;D spend was about KRW 118.6 billion in 2024, roughly 18% of revenue. The work covers lab testing, clinical-trial management, and formulation optimization to improve outcomes, and sustained R\u0026amp;D is the main engine for long-term growth and portfolio diversification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Tech Manufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHuons operates GMP-certified facilities producing injectables, tablets, and medical devices with batch-level quality control; in 2024 they reported CAPA closure rate of 98% and API yield \u0026gt;99%, supporting export revenue of KRW 210 billion (2024) and passing 6 international regulatory audits last year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Marketing and Brand Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHuons runs targeted marketing to build brand equity for its aesthetic lines and health functional foods, spending about KRW 12.3 billion on marketing in 2024 and reporting 18% annual growth in its consumer segment; activities include symposia for clinicians, booths at CES and CPhI, and SEO\/PPC plus social commerce channels. Effective positioning in dermatology and wellness helped Huons lift ASPs by 6% and gain a 4.2% share in Korea’s medical aesthetic consumables market in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Regulatory Compliance and Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating international healthcare regulations is core to Huons’ model: its regulatory affairs teams secure FDA, EMA and local approvals, enabling exports and licensing that drove 2024 international sales of KRW 210 billion (approx $160M), 28% of revenue.\u003c\/p\u003e\n\u003cp\u003eThe ongoing approvals pipeline—12 FDA\/EMA submissions and 35 country registrations in 2024—underpins licensing deals and legal market entry across Asia, Europe, and the US.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 int’l sales KRW 210B (~$160M)\u003c\/li\u003e\n\u003cli\u003e28% of total revenue (2024)\u003c\/li\u003e\n\u003cli\u003e12 FDA\/EMA submissions (2024)\u003c\/li\u003e\n\u003cli\u003e35 country registrations (2024)\u003c\/li\u003e\n\u003cli\u003eRegulatory team drives licensing deals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Logistics Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHuons runs end-to-end cold-chain logistics for temperature-sensitive drugs, sourcing APIs and excipients and delivering to 1,200+ hospitals and 4,500 pharmacies in Korea; cold-storage ops cut spoilage under 0.3% and reduced logistics cost 6.1% in FY2024.\u003c\/p\u003e\n\u003cp\u003eOptimized routes and global distributors cut lead times by 18% and support export revenue growth, which rose 22% to KRW 48.6 billion in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold-chain spoilage \u0026lt;0.3%\u003c\/li\u003e\n\u003cli\u003eServes 1,200+ hospitals, 4,500 pharmacies\u003c\/li\u003e\n\u003cli\u003eLogistics cost down 6.1% (FY2024)\u003c\/li\u003e\n\u003cli\u003eLead times cut 18%\u003c\/li\u003e\n\u003cli\u003eExports KRW 48.6B, +22% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuons: R\u0026amp;D-led GMP excellence drives KRW210B global sales, \u0026gt;99% API yield, \u0026lt;0.3% spoilage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHuons focuses on R\u0026amp;D (KRW 118.6B, 18% of revenue in 2024), GMP manufacturing with API yield \u0026gt;99% and CAPA closure 98%, regulatory submissions (12 FDA\/EMA, 35 country regs) driving KRW 210B international sales (28% of revenue), plus cold-chain logistics serving 1,200+ hospitals and 4,500 pharmacies with spoilage \u0026lt;0.3% and logistics cost down 6.1% (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eKRW 118.6B (18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl sales\u003c\/td\u003e\n\u003ctd\u003eKRW 210B (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA\/EMA subs\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountry regs\u003c\/td\u003e\n\u003ctd\u003e35\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI yield\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAPA close rate\u003c\/td\u003e\n\u003ctd\u003e98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/Pharmacies\u003c\/td\u003e\n\u003ctd\u003e1,200+\/4,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain spoilage\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you’re previewing is the actual Huons Business Model Canvas—not a mockup—and it matches exactly what you’ll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll get this same professional, ready-to-edit file in full, formatted versions suitable for presenting, sharing, and customizing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749066387833,"sku":"huons-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/huons-business-model-canvas.png?v=1772212788","url":"https:\/\/matrixbcg.com\/products\/huons-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}